Poster Abstract Session:
167. Preclinical Study with New Antibiotics and Antifungals
Friday, October 6, 2017: 12:30 PM-2:00 PM
Room: Poster Hall CD

Tracks: Adult ID, Epidemiology and Infection Control, Investigative ID, Pediatric ID


Presentations:
Evaluation of the In Vitro and In Vivo Antifungal Activity of APX001A/APX001 Against Candida auris
Emily Larkin, BA; Lisa Long, BA; Christopher Hager, BS; Karen Joy Shaw, PhD; Mahmoud Ghannoum, PhD, FIDSA
SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis
Katyna Borroto-Esoda, PhD; Stephen Barat, PhD; David Angulo, MD; Kirsty Holden, PhD; Peter Warn, PhD
In Vivo Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Murine Urinary Tract Infection Models
Shuhei Matsumoto, master's degree; Sachi Kanazawa, Ph.D; Rio Nakamura, Bachelor; Masakatsu Tsuji, Ph.D; Takafumi Sato, Ph.D; Yoshinori Yamano, Ph.D
Absorption, Distribution, and Excretion of 14C‑APX001 after Single-Dose Administration to Rats and Monkeys
Robert Mansbach, PhD; Karen J. Shaw, PhD; Michael R. Hodges, MBBS, BSc; Samantha Coleman, PhD; Michael E. Fitzsimmons, PhD
Posters
  • 1513_IDWPOSTER - upload.pdf (308.0 kB)
  • Delayed Dosing of S-033188, a Novel Inhibitor of Influenza Virus Cap-dependent Endonuclease, Exhibited Significant Reduction of Viral Titer and Mortality in Mice Infected with Influenza A Virus.
    Keita Fukao, MS; Yoshinori Ando, Ph.D.; Takeshi Noshi, MS; Makoto Kawai, Ph. D.; Ryu Yoshida, Ph. D.; Takao Shishido, PhD; Akira Naito, Ph. D.
    Posters
  • Combination vivo_final.pdf (406.5 kB)
  • Pharmacokinetic-Pharmacodynamic Target Attainment Analysis to Support VL-2397 Dose Selection for a Phase 2 Trial in Patients with Invasive Aspergillosis
    Christopher M. Rubino, Pharm.D.; Larry R. Smith, PhD; Mammen P. Mammen, MD; Andrew M. Hopkins, MBS; Elizabeth A. Lakota, Pharm.D., M.S.; Sean M. Sullivan, PhD
    DS11960558, A Water Soluble Prodrug of DS-2969b, for Intravenous Treatment of Clostridium difficile Infection
    Makiko Yamada, MS; Minoru Uchiyama, PhD; Shin-Ichi Inoue, PhD; Tsuneo Deguchi, PhD; Yoshitake Furuta, MS; Koichi Yabe, DVM, PhD; Nobuhisa Masuda, PhD
    Posters
  • IDWeek 1516.pdf (1.3 MB)
  • ZTI-01 Treatment Improves Survival of Animals Infected with Multidrug Resistant Pseudomonas aeruginosa
    Matthew B Lawrenz, PhD; Ashley Eb denDekker, BS, RLAT, LVT; Daniel E Cramer, PhD; Jon D Gabbard, PhD; Kathryn M Lafoe, BS, RALAT; Tia L Pfeffer, BA; Julie B Sotsky, PhD; Carol D Vanover, RLAT; Evelyn J. Ellis-Grosse, PhD; Jonathan M Warawa, PhD
    Posters
  • ID Week Poster UofL final.pdf (841.8 kB)
  • Delayed therapy with plasma gelsolin improves survival in murine pneumococcal pneumonia
    Zhiping Yang, MD; Susan Levinson, PhD; Thomas Stossel, MD; Mark DiNubile, MD; Lester Kobzik, MD
    In Vivo Efficacy of Humanized Exposures of Cefiderocol Compared with Cefepime (FEP) and Meropenem (MEM) against Gram-negative Bacteria in a Murine Thigh Model
    Marguerite Monogue, PharmD; Masakatsu Tsuji, Ph.D; Yoshinori Yamano, Ph.D; Roger Echols, MD, FIDSA; David P. Nicolau, PharmD, FCCP, FIDSA
    APX001A Protects Immunosuppressed Mice from Rhizopus delemar Infection
    Teclegiorgis Gebremariam, MS; Sondus Alkhazraji, PhD; Abdullah Alqarihi, MS; Nathan P. Wiederhold, PharmD; Karen Joy Shaw, PhD; Thomas Patterson, MD, FIDSA, FACP; Scott Filler, MD; Ashraf Ibrahim, PhD
    Fosfomycin (FOS) Plus Meropenem (MER) Suppresses Resistance Emergence Against P. aeruginosa (PA) PAO1 in the Hollow Fiber Infection Model (HFIM)
    Arnold Louie, M.D.; Michael Maynard, BS; Brandon Duncanson, MS; Michael Vicchiarelli, BS; George L. Drusano, M.D., FIDSA
    Good Correlation of Cefiderocol Between In Vivo Efficacy Murine Thigh/Lung Infection Models and MIC Determined in Iron-Depleted Conditions
    Yoshinori Yamano, Ph.D; Rio Nakamura, Bachelor; Takafumi Sato, Ph.D.; Masakatsu Tsuji, Ph.D; Roger Echols, MD, FIDSA
    Discovery of a Series of Potent and Selective Nucleotide Prodrug Inhibitors of Respiratory Syncytial Virus (RSV) Replication
    Steven Good, M.S.; Adel Moussa, Ph.D.; Jean-Cristophe Meillon, Ph.D.; Xiao-Jian Zhou, Ph.D.; Keith Pietropaolo, B.S.; Jean-Pierre Sommadossi, Ph.D.
    Novel immunization strategies against multi-drug resistant Gram negative bacteria
    Eman A. Youssef, M.Sc.; Lin Lin, PhD; Lina Zhang, PhD; Ashraf S. Ibrahim, PhD
    Posters
  • Hyr1 mAbs aginst AB and KPC.pdf (636.7 kB)
  • Efficacy of Oral APX001 in a Murine Model of Cryptococcal Meningitis
    Wiley A. Schell, MS; Charles Giamberardino, M.R.; Karen J. Shaw, PhD; John R Perfect, M.D., FIDSA
    Diol-Based Polymer Microparticles for Treatment of Cutaneous Aspergillosis in an Immunocompromised Murine Model
    Alexander Tatara, Ph.D.; Nathaniel Albert, MS; Emma Watson, B.S.; Antonios Mikos, Ph.D.; Dimitrios P. Kontoyiannis, MD, ScD, PhD (Hon), FACP, FIDSA, FECMM, FAAM
    In vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Staphylococcus aureus (SA) in the Murine Thigh Infection Model
    Alexander J. Lepak, M.D.; Miao Zhao, MS; Karen Marchillo, MLT; Jamie VanHecker, CVT; David R. Andes, M.D., FIDSA
    Posters
  • Omad SA ID Week 2017 V2.pdf (347.9 kB)
  • Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-Abdominal Abscess Model
    Yanan Zhao, Ph.D.; Brendan Prideaux, Ph.D.; Yoji Nagasaki, MD; Min Hee Lee, MS; Pei-Yu Chen, MS; Landry Blanc, Ph.D.; Hsinpin Ho, Ph.D.; Cornelius J. Clancy, M.D.; Minh-Hong Nguyen, MD; Veronique Dartois, Ph.D.; David Perlin, Ph.D.
    Posters
  • Perlin_PN1533.pdf (764.4 kB)
  • Nitric Oxide-Releasing Chitosan for the Treatment of Multi-Drug Resistant Superbugs
    Terry Kougoulos, PhD; Mark Schoenfisch, PhD; Pedro De Jesus Cruz, B.S.; Mona Ahonen, B.S.; Nathan Fisher, PhD
    Feasibility of Neurapheresis™ as a Therapy for Multidrug Resistant Gram-negative Bacterial Meningitis
    Christi Ballard, B.S.; Bilal Ashraf, B.S.; Tiffany Ejikeme, B.S.; Brenda Hansen, M.S.; Lefko Charalambous, B.S.; Promila Pagadala, Ph.D.; Batu K Sharma-Kuinkel, PhD; Charles Giamberardino, M.R.; Blake Hedstrom, M.A., B.A.; Laura Zitella Verbick, Ph.D.; Aaron Mccabe, Ph.D.; Shivanand P. Lad, M.D., Ph.D.; Vance G. Fowler Jr., MD; John R Perfect, M.D., FIDSA
    Evaluation of a 15-valent pneumococcal conjugate vaccine in an adult Rhesus macaque immunogenicity model
    Jinfu Xie, MSc; Robin Kaufhold, MSc; Debra Mcguinness, MSc; Yuhua Zhang, MSc; William Smith, PhD; Cecelia Giovarelli, MSc; Michael Winters, PhD; Luwy Musey, MD; Michael Kosinski, PhD; Julie Skinner, PhD
    Foley Catheter with Peri-Urethral Antimicrobial Irrigation for the Prevention of Catheter Associated Urinary Tract Infections – Assessment in an in vitro model
    Joel Rosenblatt, PhD; Ruth Reitzel, PhD; Nylev Vargas-Cruz, BS; Anne-Marie Chaftari, MD; Ray Y. Hachem, MD; Issam Raad, MD
    In Vitro Characterization of the Neurapheresis™ System for the Treatment of Cryptococcal Meningitis
    Lefko Charalambous, B.S.; Christi Ballard, B.S.; Tiffany Ejikeme, B.S.; Bilal Ashraf, B.S.; Promila Pagadala, Ph.D.; Charles Giamberardino, M.R.; Blake Hedstrom, M.A., B.A.; Laura Zitella Verbick, Ph.D.; Aaron Mccabe, Ph.D.; Shivanand P. Lad, M.D., Ph.D.; John R Perfect, M.D., FIDSA

    CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™


    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.